AI Article Synopsis

  • Neuroendocrine neoplasms (NENs) are uncommon in the head and neck, with laryngeal neuroendocrine carcinoma (NEC) being the most frequent, primarily affecting older men who smoke.
  • Approximately 700 cases have been documented, and the incidence rate is around 0.23%, leading to challenges in diagnosis and treatment due to their vague symptoms.
  • Treatment often combines surgery, chemotherapy, and radiotherapy, as illustrated by a case study of a 61-year-old female nonsmoker who received endoscopic excision and follow-up radiotherapy for supraglottic laryngeal NEC.

Article Abstract

Neuroendocrine neoplasms (NENs) are rare in the head and neck region, with the larynx being the most common site. To date, nearly 700 cases of laryngeal neuroendocrine carcinoma (NEC) have been reported in the literature, with an estimated incidence as low as 0.23%. This type of cancer is more prevalent among men aged 50-83 who are heavy smokers. NENs encompass paragangliomas and epithelial neoplasms. The latter categories include neuroendocrine tumors, or typical carcinoids, and NECs, or atypical carcinoids. Due to their nonspecific and often misleading presentation, and given the rarity of this condition, optimal management lacks standardization. Treatment typically involves a combination of surgery, chemotherapy, and radiotherapy. We present a case of supraglottic laryngeal NEC in a 61-year-old female nonsmoker. The patient underwent endoscopic excision followed by adjuvant radiotherapy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11461083PMC
http://dx.doi.org/10.1155/2024/6844193DOI Listing

Publication Analysis

Top Keywords

neuroendocrine carcinoma
8
supraglottic neuroendocrine
4
carcinoma case
4
case report
4
report literature
4
literature review
4
review neuroendocrine
4
neuroendocrine neoplasms
4
neoplasms nens
4
nens rare
4

Similar Publications

Purpose: To determine whether renal cell carcinoma metastases (RCC-Mets) to the pancreas can be differentiated from pancreatic neuroendocrine tumors (PNETs) in patients with RCC on CT or MRI at presentation.

Methods: This retrospective study included patients with biopsy-proven RCC-Mets (n = 102) or PNETs (n = 32) at diagnosis or after nephrectomy for RCC. Inter-observer agreement (Cohen kappa) was assessed in 95 patients with independent reads by two radiologists, with discrepancies resolved by consensus for final analysis.

View Article and Find Full Text PDF

Purpose: We aimed to compare the diagnostic performance of 68Ga-FAPI-04 (FAPI) in comparison to 68Ga-DOTATATE (SSTR) PET/CT for patients presenting with recurrent medullary thyroid carcinoma (MTC).

Patients And Methods: Sixteen MTC patients with elevated calcitonin levels (>150 pg/mL) underwent FAPI and SSTR PET/CT. Two nuclear medicine physicians evaluated all images, categorizing lesions into locoregional metastases, mediastinal lymph nodes (LNs), liver, and bone metastases.

View Article and Find Full Text PDF

Medullary thyroid carcinoma (MTC), a rare neuroendocrine tumor comprising 3-5% of thyroid cancers, arises from calcitonin-producing parafollicular C cells. Despite aggressive behavior, surgery remains the primary curative treatment, with limited efficacy reported for radiotherapy and chemotherapy. Recent efforts have explored the pathogenetic mechanisms of MTC, identifying it as a highly vascularized neoplasm overexpressing pro-angiogenic factors.

View Article and Find Full Text PDF

A seven-year-old spayed female dog presented with multiple, small oval-shaped masses on the abdominal skin. The excised tissue was submitted for histopathological evaluation. Routine histology revealed basaloid nodules with stippled chromatin and pleomorphic nuclei.

View Article and Find Full Text PDF

Primary small cell neuroendocrine carcinoma of the prostate is extremely rare, highly aggressive, and has a very poor prognosis, with an overall survival typically not exceeding one year. Standard treatment is generally based on the regimen for small cell lung cancer (SCLC), with guidelines recommending etoposide combined with cisplatin (EP regimen) as the first-line treatment. However, their therapeutic effects are limited.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!